Orchard Therapeutics (NASDAQ:ORTX) vs. Miromatrix Medical (NASDAQ:MIRO) Financial Review

Orchard Therapeutics (NASDAQ:ORTXGet Rating) and Miromatrix Medical (NASDAQ:MIROGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Insider and Institutional Ownership

56.5% of Orchard Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of Miromatrix Medical shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Orchard Therapeutics and Miromatrix Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchard Therapeutics 1 2 3 0 2.33
Miromatrix Medical 0 0 1 0 3.00

Orchard Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 1,451.72%. Miromatrix Medical has a consensus price target of $22.00, indicating a potential upside of 456.96%. Given Orchard Therapeutics’ higher probable upside, equities research analysts plainly believe Orchard Therapeutics is more favorable than Miromatrix Medical.

Valuation & Earnings

This table compares Orchard Therapeutics and Miromatrix Medical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orchard Therapeutics $1.67 million 43.73 -$144.58 million ($1.22) -0.48
Miromatrix Medical $30,000.00 2,707.99 -$14.67 million N/A N/A

Miromatrix Medical has lower revenue, but higher earnings than Orchard Therapeutics.

Profitability

This table compares Orchard Therapeutics and Miromatrix Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orchard Therapeutics N/A -68.98% -46.08%
Miromatrix Medical -62,805.01% -38.24% -34.83%

Summary

Orchard Therapeutics beats Miromatrix Medical on 6 of the 11 factors compared between the two stocks.

Orchard Therapeutics Company Profile (Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Miromatrix Medical Company Profile (Get Rating)

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

Want More Great Investing Ideas?

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.